View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
March 1, 2022

Celyad to halt Phase Ib trial of CAR T therapy for colorectal cancer

The voluntary pause comes after the company received reports of two fatalities with similar pulmonary findings.

Celyad Oncology has decided to voluntarily halt the Phase Ib clinical trial of chimeric antigen receptor T cell (CAR T) therapy CYAD-101, to treat refractory metastatic colorectal cancer patients.

Named CYAD-101-002 (KEYNOTE-B79), the trial is part of a partnership with Merck Sharp & Dohme (MSD), through a subsidiary.

The trial is assessing Celyad’s TCR Inhibitory Molecule (TIM)-based allogeneic NKG2D CAR T cell investigational therapy CYAD-101 given along with FOLFOX chemotherapy and subsequently by Keytruda (pembrolizumab), in refractory metastatic colorectal cancer patients.

The move comes after Celyad obtained reports of two fatalities with comparable pulmonary findings.

To assess these events, the company will voluntarily halt subject dosing and enrolment in the CYAD-101-002 trial.

At present, it is studying these reports and analysing any similar events in other subjects who received the treatment in the trial.

Furthermore, Celyad is notifying the regulatory authorities on the development, which could necessitate further actions of the company. 

The company anticipates providing further trial updates soon.

Celyad Oncology CEO Filippo Petti said: “Our primary commitment is to maintain patient safety, which is why we decided to place the trial on hold while we investigate these events. 

“In 25 patients previously treated with CYAD-101 in the alloSHRINK Phase I trial, which evaluated the TIM-based investigational candidate for the treatment of advanced mCRC, no-dose limiting toxicities were reported. 

“Lastly, we anticipate no impact on our shRNA-based candidates, including CYAD-211 currently under investigation for the treatment of multiple myeloma.” 

In December last year, the company dosed the first subject in the Phase Ib trial of CYAD-101.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena